ANIK

Anika Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↑ 8/10
  • Value↓ 2/10
Anika Therapeutics sales and earnings growth
ANIK Growth
Good
  • Revenue Y/Y↑ 5.07%
  • EPS Y/Y↑ 79.59%
  • FCF Y/Y↑ 126.30%
Anika Therapeutics gross and profit margin trends
ANIK Profitability
Neutral
  • Gross margin ↑ 58.60%
  • EPS margin↓ -9.50%
  • ROIC 5Y↓ -27.24%
Anika Therapeutics net debt vs free cash flow
ANIK Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Anika Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Medical Devices stocks